Quality is not a cost centre. It is a return on investment.
In July 2025, FDA’s Office of Pharmaceutical Quality made the economic and public-health case for mature quality management. This page distils that argument — the cost curve, the cost of poor quality, and the shortage link — into a practitioner-grade reference.
Quality is not all-or-nothing. It is a cost curve.
FDA models the relationship between investment in quality and total cost as a curve with four scenarios. As investment rises toward an optimum, total costs fall — driven by efficiency and less waste — then rise again only past the point of diminishing returns. Select a scenario.
Maximum profit at minimum total cost.
Lean Six Sigma process optimisation plus advanced manufacturing technologies. Extensive decreases in the cost of poor quality — deviations and yield loss fall — while profit is reinvested into R&D, infrastructure, and advanced technology, creating a competitive moat.
- ›Digital-twin schedule optimisation lifted lab productivity 40–50%
- ›Profits reinvested into R&D and reliable supply
- ›Strong reputation as a competitive advantage
Most of the cost sits below the waterline.
When poor quality management contributes to shortages, the visible costs — recalls, lost revenue — are only the tip. Below the surface sit indirect and intangible costs borne by patients, health-care systems, and society. Select a population.
Two-thirds of supply-chain challenges begin as a quality issue.
The public-health cost of poor quality is measured in shortages — and shortages are measured in patient harm. These are the specific cases FDA cites.
US shortage associated with increased mortality among patients with septic shock (Vail et al., JAMA 2017).
2023 chemotherapy shortages forced less-optimal alternatives across a broad range of cancers (ASCO guidance).
Shortage altered antimicrobial prescribing and raised C. difficile risk across 88 US medical centers.
Multi-country shortage described as an escalating public-health crisis in pediatric care.
Shortage threatened prevention of mother-to-child transmission of syphilis.
Ongoing shortage caused documented disruption to patients managing ADHD.
Beyond patients and providers, poor quality management carries societal costs: less funding for innovation (a 30% manufacturing-efficiency gain could generate $1–12.3 trillion in social value through R&D reinvestment), the emergence of treatment-resistant disease, ethical rationing dilemmas, and environmental harm from inefficient, wasteful manufacturing.
“We know that about two thirds of medicine supply chain challenges begin as a quality issue. Shortages of medicines only exacerbate the quality issues that have been there all along.
“Talk about changed practice — what I’ve had to do is drop everything else. My whole job becomes obtaining that drug.
“It just feels professionally like we’re not doing our job for the patient… “we just don’t have the drug to treat you.” I never would think I would have to say that.
Put a number on your own cost of poor quality.
Estimate what defects, scrap, and recall exposure cost you today — and the ROI band of moving up one maturity level, anchored to FDA’s cited case studies.
Source: FDA / CDER Office of Pharmaceutical Quality, “Quality Management Initiatives in the Pharmaceutical Industry: An Economic Perspective” (July 2025). All figures are FDA’s; SPEQ’s applications are labelled as illustrations.